Endocrine therapy in DCIS: how do we proceed?
作者信息
Dixon J Michael, Jane Macaskill E
出版信息
Breast J. 2012 Jul-Aug;18(4):295-8. doi: 10.1111/j.1524-4741.2012.01263.x.
Abstract
摘要
相似文献
1
Endocrine therapy in DCIS: how do we proceed?导管原位癌的内分泌治疗：我们该如何进行？
Breast J. 2012 Jul-Aug;18(4):295-8. doi: 10.1111/j.1524-4741.2012.01263.x.
2
Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.绝经后女性行乳房切除术治疗 DCIS：芳香化酶抑制剂的潜在作用。
Breast J. 2012 Jul-Aug;18(4):299-302. doi: 10.1111/j.1524-4741.2012.01267.x. Epub 2012 Jun 11.
3
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.COX-2表达可预测乳腺导管原位癌患者的早期复发和芳香化酶抑制剂耐药性，并且是治疗靶点。
Br J Cancer. 2014 Jul 8;111(1):46-54. doi: 10.1038/bjc.2014.236. Epub 2014 May 29.
4
5
[New results of endocrine therapy of breast cancer (the role of Aromasin)].乳腺癌内分泌治疗的新成果（阿那曲唑的作用）
Vopr Onkol. 2004;50(6):729-36.
6
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.深度时间：乳腺癌辅助内分泌治疗的长短考量
J Clin Oncol. 2012 Mar 1;30(7):684-6. doi: 10.1200/JCO.2011.40.1455. Epub 2012 Jan 23.
7
The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.芳香化酶抑制剂在原位导管癌（雌激素受体阳性/孕激素受体阴性/Her-2/neu受体阳性模式）治疗中的作用。
Am J Surg. 2007 Aug;194(2):272-3. doi: 10.1016/j.amjsurg.2006.07.022.
8
Exemestane or tamoxifen?依西美坦还是他莫昔芬？
Lancet. 2007 May 12;369(9573):1600; author reply 1600-1. doi: 10.1016/S0140-6736(07)60740-5.
9
Switching to aromatase inhibitors in early breast cancer.早期乳腺癌改用芳香化酶抑制剂。
Lancet. 2007 Feb 17;369(9561):533-5. doi: 10.1016/S0140-6736(07)60201-3.
10
[Advancement in endocrine therapy for breast cancer].[乳腺癌内分泌治疗的进展]
Ai Zheng. 2007 Apr;26(4):440-4.
Zotero 插件